CORMEDIX INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
CORMEDIX INC. (CRMD) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $4.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $4.08M, a 52.56% increase year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $4.58M, a 30.91% increase year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $3.59M, a 200.71% increase year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $4.07M, a 231.21% increase year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $13.83M, a 125.68% increase from fiscal 2024.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $6.13M, a 11.56% increase from fiscal 2023.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $5.49M, a 35.00% increase from fiscal 2022.
- CORMEDIX INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $4.07M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.08M 10-Q · filed 2026-08-13 | $8.67M 10-Q · filed 2026-08-13 | $12.26M derived: sum of 3 quarters · filed 2026-08-13 | $16.32M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $4.58M 10-Q · filed 2026-05-14 | $8.17M derived: sum of 2 quarters · filed 2026-05-14 | $12.24M derived: sum of 3 quarters · filed 2026-05-14 | $14.91M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.65M derived: sum of 2 quarters · filed 2026-03-05 | $10.33M derived: sum of 3 quarters · filed 2026-08-13 | $13.83M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $4.07M 10-Q · filed 2025-11-12 | $6.74M derived: sum of 2 quarters · filed 2026-08-13 | $10.24M 10-Q · filed 2025-11-12 | $11.44M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-13 | $2.68M 10-Q · filed 2025-08-07 | $6.18M 10-Q · filed 2026-08-13 | $6.18M 10-Q · filed 2025-08-07 | $7.37M derived: sum of 3 quarters · filed 2026-08-13 | $8.60M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $3.50M 10-Q · filed 2026-05-14 | $3.50M 10-Q · filed 2025-05-06 | $4.69M derived: sum of 2 quarters · filed 2026-05-14 | $5.92M derived: sum of 3 quarters · filed 2026-05-14 | $7.18M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.42M derived: sum of 2 quarters · filed 2026-03-05 | $3.68M derived: sum of 3 quarters · filed 2026-03-05 | $6.13M 10-K · filed 2026-03-05 | $6.13M 10-K · filed 2025-03-25 | ||
| 2024-09-30 | $1.23M 10-Q · filed 2025-11-12 | $2.49M derived: sum of 2 quarters · filed 2025-11-12 | $4.94M 10-Q · filed 2025-11-12 | $6.15M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $1.26M 10-Q · filed 2025-08-07 | $3.71M 10-Q · filed 2025-08-07 | $4.93M derived: sum of 3 quarters · filed 2025-08-07 | $5.93M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $2.44M 10-Q · filed 2025-05-06 | $3.66M derived: sum of 2 quarters · filed 2025-05-06 | $4.66M derived: sum of 3 quarters · filed 2025-05-06 | $5.72M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.22M derived: sum of 2 quarters · filed 2025-03-25 | $3.28M derived: sum of 3 quarters · filed 2025-03-25 | $5.49M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $1.00M 10-Q · filed 2024-10-30 | $2.06M derived: sum of 2 quarters · filed 2024-10-30 | $4.28M 10-Q · filed 2024-10-30 | $5.15M derived: sum of 4 quarters · filed 2024-10-30 | |||
| 2023-06-30 | $1.06M 10-Q · filed 2024-08-14 | $3.27M 10-Q · filed 2024-08-14 | $4.15M derived: sum of 3 quarters · filed 2024-08-14 | $5.13M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $2.22M 10-Q · filed 2024-05-09 | $3.09M derived: sum of 2 quarters · filed 2024-05-09 | $4.07M derived: sum of 3 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $874.05K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.86M derived: sum of 2 quarters · filed 2024-03-12 | $4.07M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $983.52K 10-Q · filed 2023-11-14 | $3.20M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |